Labcorp Launches Global Trial Connect to Accelerate Clinical Trials
Labcorp (NYSE: LH) has launched Labcorp Global Trial Connect, a suite of digital solutions to enhance the efficiency of clinical trials.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Labcorp (NYSE: LH) has launched Labcorp Global Trial Connect, a suite of digital solutions to enhance the efficiency of clinical trials. Announced on June 17, 2024, these tools aim to accelerate trial processes at investigator sites by simplifying workflows, improving patient experiences, and aiding biopharma sponsors. Key features include site enablement resources to identify study opportunities and enhance diversity, supply readiness support to prevent delays, and workflow facilitation for better data integration and error reduction. Available to current Labcorp Central Laboratory clients, these solutions promise to speed up study initiation and maintain momentum.
Positive
- Launch of Labcorp Global Trial Connect could enhance trial efficiency, potentially speeding up market entry for therapies.
- Site enablement resources may improve patient recruitment and diversity in clinical trials.
- Supply readiness support aims to reduce trial delays and kit waste, improving startup efficiency.
- Workflow facilitation features might reduce errors and queries, improving data accuracy.
- 24/7 site support and on-demand tools could maintain study momentum, benefiting trial timelines.
Negative
- The new solutions are only available to current Labcorp Central Laboratory clients, limiting accessibility.
- High expectations for the new suite may not be met, potentially leading to investor disappointment.
- Implementation and integration of new systems could present short-term operational challenges.
Details
News Market Reaction – LH
The recorded move for LH in the trading session of this news was +0.84%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows
BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites.
"The patient-investigator-biopharma sponsor relationship is at the foundation of a successful clinical trial. Global Trial Connect simplifies the investigator workflow, improves the patient experience and ultimately enables biopharma sponsors to bring therapies to market faster," said Jon DiVincenzo, EVP and President, Central Laboratories and International at Labcorp. "As the world's leading central laboratory, Labcorp is dedicated to improving the pace of clinical trials focusing on the investigator site experience from study initiation to patient recruitment and data collection."
Labcorp Global Trial Connect, available to current Labcorp Central Laboratory clients, incorporates complementary digital and data solutions that help accelerate clinical study startup, maintain study momentum and increase study throughput. Capabilities include:
- Site enablement resources – to identify new study opportunities, enhance patient access and recruitment and improve diversity in clinical trials.
- Supply readiness support – to increase study startup efficiencies, reduce trial delays and reduce supply and kit waste.
- Site workflow facilitation – to help integrate sample collection and tracking data, provide visibility and actionable analytics to both sites and sponsors, and reduce errors, queries, holds and data revisions through eRequisition functionality.
- Study management and investigator support – to accelerate study startup and maintain study momentum with 24/7 site support and on-demand tools and trainings.
For more information, visit LabcorpGlobalTrialConnect.com.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-global-trial-connect-to-accelerate-clinical-trials-302174129.html
SOURCE Labcorp
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.